Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for non-alcoholic fatty liver disease
IRCT20201220049772N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoint: Insulin resistance. Started Feb 2021; status: completed.
02
Drugs
acetylcysteine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20201220049772N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201220049772N1.